Nature Reviews Rheumatology | 2021
Topical NSAIDs come out top for knee OA
Abstract
The first randomized controlled trial of belimumab focusing on individuals with systemic lupus erythematosus (SLE) of Black African ancestry suggests that belimumab could be a suitable treatment option for this group of patients. The international, double blind, placebocontrolled trial of monthly intravenous belimumab (10 mg/kg) in patients with SLE who selfidentified as Black did not meet its primary end point of improvement in the SLE responder index with modified proteinuria scoring at week 52. However, disease did improve in those treated with belimumab compared with placebo, with no new safety signals.